ABL1 and B-cell acute lymphoblastic leukemia: BCR-ABL+ B-cell acute lymphoblastic leukemia (B-ALL) is a treatment-refractory subtype of B-ALL with a ~50% 3-year overall survival following the use of cytotoxic chemotherapeutics in combination with targeted BCR-ABL kinase inhibitors7,8.